



(51) International Patent Classification:

C07D 495/20 (2006.01) A61P 25/00 (2006.01)
A61K 31/444 (2006.01)

(21) International Application Number:

PCT/US2010/056180

(22) International Filing Date:

10 November 2010 (10.11.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09382246.8 16 November 2009 (16.11.2009) EP
61/298,629 27 January 2010 (27.01.2010) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BENITO COLLADO, Ana Belen** [ES/ES]; Lilly S.A., Avendia de la Industria 30, 28108 Alcobendas, Madrid (ES). **DIAZ BUEZO, Nuria** [ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES). **JIMENEZ-AGUADO, Alma Maria**


[ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES). **LAFUENTE BLANCO, Celia** [ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES). **MARTINEZ-GRAU, Maria Angeles** [ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES). **PEDREGAL-TERCERO, Concepcion** [ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES). **TOLEDO ESCRIBANO, Miguel Angel** [ES/ES]; Lilly, S.A., Avendia de la Industria 30, Madrid (ES).

(74) Agents: **TUCKER, R., Craig** et al.; Eli Lilly and Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS



(57) Abstract: As ORL-1 receptor antagonist of the formula I, its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful; in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraine.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*